<DOC>
	<DOCNO>NCT00338624</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness oxybutynin extend release tablet 10 mg plus tamsulosin HCl 0.4 mg treatment low urinary tract symptom measure change total International Prostate Symptom Score ( I-PSS ) baseline Week 12 Final Visit .</brief_summary>
	<brief_title>An Effectiveness Safety Study Comparing Oxybutynin Chloride Plus FLOMAX ( Tamsulosin HCl ) Placebo Plus FLOMAX ( Tamsulosin HCl ) Treatment Lower Urinary Tract Symptoms .</brief_title>
	<detailed_description>The objective double-blind ( neither patient physician know whether drug placebo take , dosage ) , randomize ( patient assign different treatment base chance ) , parallel group trial evaluate safety effectiveness oxybutynin extend release tablet 10 mg per day 12 week conjunction alpha-blocker treatment low urinary tract symptom ( LUTS ) . The hypothesis study oxybutynin extend release tablet 10 mg plus tamsulosin 0.4 mg effective tamsulosin 0.4 mg plus placebo treatment low urinary tract symptom measure change total International Prostate Symptom Score ( I-PSS ) baseline Week 12 Final Visit . Safety assessment include Peak Flow Rate ( PFR ) Post-Void Residual ( PVR ) volume , adverse event , vital sign physical exam . Patients receive oxybutynin extend release 10 mg plus tamsulosin 0.4 mg placebo plus tamsulosin 0.4 mg every day 12 week .</detailed_description>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Urination Disorders</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Diagnosis low urinary tract symptom urgency frequency without urge incontinence least 4 week 0.4 mg/day tamsulosin therapy International Prostate Symptom Score ( IPSS ) &gt; =13 irritative component IPSS score &gt; = 8 max flow &gt; = 8ml/sec voided volume &gt; = 125 ml , postvoid residual volume &lt; = 150 ml two occasion . Clinically significant medical problem organ abnormality pathology ProstateSpecific Antigen ( PSA ) &gt; = 4 ng/ml history inability empty bladder completely uncontrolled narrow angle glaucoma history prostate surgery treatment history significant gastrointestinal problem .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>low urinary tract symptom</keyword>
	<keyword>DITROPAN XL</keyword>
	<keyword>oxybutynin extend release tablet</keyword>
</DOC>